Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer

NCT06787612 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

220

Enrollment

INDUSTRY

Sponsor class

Conditions

Ovarian Cancer
Fallopian Tube Cancer
Primary Peritoneal Cancer

Interventions

DRUG: Ubamatamab
DRUG: Bevacizumab
DRUG: Cemiplimab
DRUG: Fianlimab
DRUG: PLD
DRUG: Sarilumab

Sponsor

Regeneron Pharmaceuticals